Press Release – May 6, 2024
On April 24, 2024, we were notified that Clarivate has ceased coverage of the European Review for Medical and Pharmacological Sciences in Web of Science. Clarivate determined that the journal did not meet the following criteria: appropriate citations to the literature. Some articles were found to lack proper acknowledgment of relevant literature on the subject.
In response to numerous inquiries from authors who have contributed to this journal, we want to reassure you that articles already indexed will remain in Web of Science if they were published before February 28, 2024. Clarivate has not conducted a retrospective removal of content before this date.
However, articles published after this specific date will not be indexed. Regrettably, this decision rests solely with Clarivate and is beyond our domain. The journal reserves the right to make a formal appeal. European Review for Medical and Pharmacological Sciences is seizing this opportunity to collaborate closely with Web of Science and maintain high editorial standards.
The journal is contacting the authors to inform them about the current status; however, if you have doubts about the indexing status of your article, you can contact the editorial team at submission.europeanreview@verduci.it
Press Release – January 26, 2024
Announcing new updated editorial guidelines for Special Issues and Supplements
European Review for Medical and Pharmacological Sciences has updated its editorial guidelines concerning the publication of Special Issues and Supplements.
Following the new DOAJ criteria and COPE guidelines, released in November and May 2023, respectively, the new guidelines update the existent criteria concerning the authorship and Guest Editors’ role within the articles included in Special Issues and Supplements, with a particular focus on the peer-review process, the contribution of authors and Guest Editors in each article and the conflicts of interest.
The new guidelines are already available in the Instructions for Authors.
Press Release – June 28, 2022
Eur Rev Med Pharmacol Sci announces the new 2021 Impact Factor release
European Review for Medical and Pharmacological Sciences is pleased to share the great success achieved this year with the new Impact Factor of 3.784. We would like to thank all our Authors who are the ones ultimately responsible for the significant growth of the Journal and invite them to submit new research.
Press Release – August 5, 2021
Eur Rev Med Pharmacol Sci indexed in DOAJ
We are glad to announce that Eur Rev Med Pharmacol Sci has just been indexed in the Directory of Open Access Journals (DOAJ) thanks to the remarkable improvements that have been made in the journal’s quality over the last few years. DOAJ is a well-known community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals (https://doaj.org/).
Press Release – July 15, 2021
Announcing changes in the Editorial Board
Verduci Editore is pleased to announce the appointment of Prof. Camillo Ricordi as Editor-in-Chief and Prof. David Della Morte Canosci as Co-Editor-in-Chief of European Review for Medical and Pharmacological Sciences.
Verduci Editore is deeply grateful to Prof. Antonio Gasbarrini and to Prof. Aldo V. Greco for their service as Editors in Chief and for their contribution to the growth of European Review for Medical and Pharmacological Sciences over the past decades. They supported the journal handling a successful and ongoing increase and contributing in different ways to the development of the journal.
Editor in Chief,
Camillo Ricordi, MD, FNAI
Prof. Camillo Ricordi, is the Stacy Joy Goodman Professor of Surgery and Director of the Diabetes Research Institute and the Cell Transplant Center at the University of Miami, Miami, Florida, USA.
Acknowledged as a leading scientist in diabetes cure-focused research and cell transplantation, Ricordi is known for inventing the method that made it possible to isolate large numbers of insulin-producing cells from the human pancreas and for performing the first series of successful clinical islet allotransplants that reversed diabetes. The procedure is now used worldwide, including the first successful NIH-funded, FDA Phase 3 multicenter trial completed by the NIH Clinical Islet Transplantation Consortium where Ricordi served as Chairperson of the Steering Committee for over a decade. His research interests include reversal of autoimmunity, transplant tolerance, modulation of immunity and inflammation and regenerative medicine, to prevent or treat chronic degenerative disease conditions, and to prolong healthy lifespan.
When the COVID-19 pandemic emerged, Prof. Camillo Ricordi led the international team that successfully completed the first FDA-approved double-blind, randomized, placebo-controlled clinical trial to treat severe cases of COVID-19 ARDS with Umbilical Cord derived Mesenchymal Stem Cell infusions. The unprecedented results allowed for significantly improved time to recovery and patient survival in subjects treated. Ricordi and his collaborators have recently launched the Fit4Pandemic program (www.fit4pandemic.com) to help the general population become resistant to the most severe forms of viral infections, as well as to prevent or halt the progression of autoimmune diseases and age-related chronic degenerative conditions, to prolong healthy lifespan.
Prof. Camillo Ricordi has received numerous honors and awards, including the Outstanding Scientific Achievement Award by the American Diabetes Association. He was Knighted by the President of the Republic of Italy in the highest Order of the Republic (the Order of Merit), and was inducted into the National Academy of Inventors, USA, for contributing outstanding inventions that have made a tangible impact on the quality of life, economic development, and welfare of society. He is also serving on the Supreme Council of Health (Consiglio Superiore di Sanità) of the Ministry of Health of Italy.
Camillo Ricordi is author of over 1,150 scientific publications that have been cited over 45,700 times (H-index 102).
Co-Editor-in-Chief,
David Della Morte Canosci, MD, PhD
Prof. David Della Morte Canosci serves as an Associate Professor of Neurology at the University of Miami, Miami, USA. Since 2013, he is also Associate Professor of Internal Medicine, Department of Systems Medicine, University of Tor Vergata, Rome, Italy, and a collaborator of the San Raffaele Open Rome, Italy. Prof. Della-Morte is involved in both basic and clinical science in the field of aging, metabolic, genetic, cardiovascular, and cerebrovascular disease. His current research focus is to clarify the pathological pathways linking metabolic diseases with cognitive impairment typical of elderly patients and with genetic disorders. Prof. Della Morte Canosci authored more than 200 scientific articles in international peer-reviewed journals. He was recipient of several grants from American Heart Association and NIH and was awarded from many Scientific Societies. He is on the board membership of several journals, and a member of The European Foundation for the Study of Diabetes and other important professional organizations.